GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
48 hedge funds and large institutions have $9.16M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 19 reducing their positions, and 23 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.78% less ownership
Funds ownership: 23.94% → 20.16% (-3.8%)
20% less funds holding
Funds holding: 60 → 48 (-12)
42% less capital invested
Capital invested by funds: $15.7M → $9.16M (-$6.53M)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
63% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crystalline Management
Montreal, Quebec,
Canada
|
+$234K |
| 2 |
BNP Paribas Asset Management
Paris,
France
|
+$170K |
| 3 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$164K |
| 4 |
PCM
PenderFund Capital Management
Vancouver,
British Columbia, Canada
|
+$99.9K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.02M |
| 2 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$417K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$233K |
| 4 |
State Street
Boston,
Massachusetts
|
-$230K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$168K |
GRNA Hedge Fund Activity: Q2 2023 in Review
48 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q2 2023, worth a combined $9.16M — down 42% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of GRNA and 12 opened new positions — a net loss of 11 holders — while 19 trimmed existing stakes and 7 added.
The largest buyer was Crystalline Management, opening a new position worth an estimated $234K. The largest seller was BlackRock, cutting an estimated $1.02M.
- 48 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q2 2023, down from 60 in Q1 2023.
- Funds reported $9.16M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q2 2023, down 42% quarter-over-quarter.
- 12 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q2 2023 and 23 closed out, a net change of -11 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q2 2023 was Crystalline Management, an estimated $234K added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q2 2023 was BlackRock, an estimated $1.02M sold.
Based on aggregated 13F filings for Q2 2023.